Mérieux Equity Partners
Mérieux Equity Partners is a Lyon-based European private equity firm founded in 2009 that invests exclusively in Healthcare and Nutrition companies via two platforms: Innovation (seed to Series B, €3–15m) and Buyout (MP4 at €568m, €20–80m), managing over €1.6bn in AUM.
- Company typePrivate
- Founded2009
- HeadquartersLyon, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Mérieux Equity Partners does
Mérieux Equity Partners is a healthcare-specialized European private equity and venture capital firm founded in 2009 and headquartered in Lyon, France, with a second office in Paris. The firm invests exclusively across the Healthcare and Nutrition sectors through two dedicated platforms: an Innovation platform (Mérieux Innovation 2, targeting €3–15m tickets in seed-to-Series B companies with minority ownership, focused on diagnostics, therapeutics, biodrugs, medtech and pharma services) and a Buyout platform (Mérieux Participations 4, closed at €568m above its €500m target, deploying €20–80m majority or minority tickets in profitable, fast-growing healthcare companies). Across both vehicles the firm manages more than €1.6bn in third-party capital and has completed 60+ investments since inception.
The firm benefits from a longstanding affiliation with Institut Mérieux (founded 1897), parent of bioMérieux, granting access to scientific, commercial and operational networks across European healthcare. It is registered with the French Autorité des Marchés Financiers (AMF) under GP-18000009 since June 2018, is a UN PRI signatory, holds the Tibi Label (2024), and is a member of the European Healthcare Private Equity Association. The investment team of 18 professionals includes PhDs in pharmacy and pharmacology, former operating executives at bioMérieux, Mérieux NutriSciences, and Institut Mérieux, plus alumni of specialist healthcare PE firms such as Keensight Capital, ArchiMed, eureKARE, and Cathay Capital.
Revenue is generated through a standard private equity model: recurring management fees on committed/invested capital across its fund vehicles, supplemented by performance-based carried interest on successful exits. Customers effectively split between (i) institutional LPs sourcing diversified European healthcare mandates and (ii) portfolio companies receiving capital, board-level support, and sector network access. Notable recent transactions include acquisitions of Curea Medical, InnoSyn, Labquality, Piercan and a minority stake in Health in Code; venture investments in Ona Therapeutics, deepull, SeqOne Genomics and Broken String Biosciences; and exits including Plantex (to Nactarome), GTP Bioways (to Olon), Mabtech (to EQT) and Swixx Biopharma (to SK Capital and Bain Capital Life Sciences).
Mérieux Equity Partners firmographics
Firmographics- Name
- Mérieux Equity Partners
- Legal name
- MERIEUX EQUITY PARTNERS SAS
- Website
- https://merieux-partners.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mérieux Equity Partners is a Lyon-based European private equity firm founded in 2009 that invests exclusively in Healthcare and Nutrition companies via two platforms: Innovation (seed to Series B, €3–15m) and Buyout (MP4 at €568m, €20–80m), managing over €1.6bn in AUM.
- Ownership category
- akta.pro rank
Mérieux Equity Partners industry classification
Industry- Product category
- Healthcare Private Equity & Venture Capital
- NAICS
- Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (525990)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)
- akta.pro secondary industry
- Venture Debt Providers (FSANAAAL)
Keywords
Where Mérieux Equity Partners is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Mérieux Equity Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Management Fees: The firm charges management fees on committed capital from their funds (Mérieux Innovation 2, MP4, and other vehicles). They manage third-party capital and are AMF-registered.
- Carried Interest: Performance-based carried interest from successful exits of portfolio companies across their investment funds.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Mérieux Equity Partners product offering
Product offeringCore offering
Mérieux Equity Partners is a healthcare-specialized private equity investment firm that manages third-party capital through two dedicated platforms: an Innovation platform (seed to Series B, €3m-€15m tickets, minority stakes) supporting innovative medical solutions, and a Buyout platform (€20m-€80m tickets, majority or minority stakes) investing in profitable, fast-growing healthcare companies. The firm manages €1.6bn+ in assets under management across funds including Mérieux Participations 4 (MP4, closed at €568m) and Mérieux Innovation 2.
Product overview
Mérieux Equity Partners is a healthcare-specialized investment firm that does not offer a product in the traditional sense. Rather, the company operates two investment platforms: Innovation (venture capital supporting innovative medical solutions from seed to series B) and Buyout (growth and buyout investments in profitable healthcare companies). The firm manages multiple funds including Mérieux Participations 4 (MP4), Mérieux Innovation 2, and others, and has a portfolio of healthcare investments across diagnostics, biotech, medtech, animal health, and pharma services sectors.
Differentiator
Problem solved
Functional benefit
Products and services
- Innovation Platform (Venture Capital)
- Buyout Platform (Growth Buyout)
- Mérieux Participations 4 (MP4) Fund
- Mérieux Innovation 2 (MI2) Fund
- Mérieux Participations 3 (MP3) Fund
Quantifiable outcome
- 60+ investments completed since 2009
- +2 more outcomes
Companies that use Mérieux Equity Partners
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
Mérieux Equity Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Mérieux Equity Partners partnerships and signals
Strategic signalScale indicators6 records
Recent moves10 records
Expansion highlights6 records
Mérieux Equity Partners competitors and assessment
Company assessmentDirect peers
- Keensight Capital: Paris-based European growth PE firm exclusively focused on technology and healthcare. Direct competitor for healthcare mid-market buyout deals across Europe and overlapping LP base with Mérieux.
- ArchiMed: France-headquartered PE firm dedicated to healthcare with growth and buyout strategies across Europe. Closest direct competitor given similar AUM scale, healthcare-only mandate, and Buyout-led model.
- GHO Capital Partners: London-based PE firm exclusively focused on European healthcare, operating across growth buyouts. Directly comparable strategy, mandate, and target company profiles to Mérieux's Buyout platform.
- Andera Partners: French PE/VC firm with dedicated Life Sciences and Healthcare strategies covering venture through growth. Comparable to Mérieux's dual Innovation/Buyout platform with overlapping French and European healthcare deal sourcing.
- Sofinnova Partners: Paris-based leading European life sciences VC investing across biopharma, medtech, and digital health from early-stage to crossover. Closest direct competitor to Mérieux's Innovation platform.
Broad incumbents
- EQT Life Sciences: European healthcare/life-sciences growth investor within broader EQT platform. Larger AUM and global reach make EQT a broader incumbent overlapping with Mérieux on growth-stage healthcare deals.
- Bain Capital Life Sciences: Global healthcare-dedicated PE/VC within Bain Capital. Recently acquired Swixx BioPharma from Mérieux. Larger AUM and global mandate make it a broad incumbent competing for upper-end deals.
- IK Partners: European mid-market PE firm with healthcare among key verticals. Co-exited Mabtech with Mérieux. Comparable European mid-market focus with broader sector mandate.
- Novo Holdings: Danish healthcare-dedicated investment firm with venture, growth, and buyout strategies globally. Comparable healthcare-only focus with substantially larger AUM and broader geographic reach than Mérieux.
Regional players
- HealthTech investor (CapHorn): French growth-stage investor with strong healthcare and tech focus. Overlaps with Mérieux Innovation on French Series A/B healthcare deals; smaller scale and narrower mandate.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Mérieux Equity Partners social profiles
Digital presenceMérieux Equity Partners compliance and trust
Trust signalCompliance7 records
Mérieux Equity Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mérieux Equity Partners leadership team
Management profileNumber of profiles
Profiles16 records
Mérieux Equity Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mérieux Equity Partners M&A and investment
M&A and investmentM&A6 records
Investments60 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mérieux Equity Partners
What does Mérieux Equity Partners do?
Mérieux Equity Partners is a healthcare-specialized private equity investment firm that manages third-party capital through two dedicated platforms: an Innovation platform (seed to Series B, €3m-€15m tickets, minority stakes) supporting innovative medical solutions, and a Buyout platform (€20m-€80m tickets, majority or minority stakes) investing in profitable, fast-growing healthcare companies. The firm manages €1.6bn+ in assets under management across funds including Mérieux Participations 4 (MP4, closed at €568m) and Mérieux Innovation 2.
Is Mérieux Equity Partners a public or private company?
Mérieux Equity Partners is a private company. It is classified as corporate owned and is currently operating.
When was Mérieux Equity Partners founded?
Mérieux Equity Partners was founded in 2009. It employs 11 to 50 people.
Where is Mérieux Equity Partners based?
Mérieux Equity Partners is headquartered in Lyon, France, in the Europe region.
How does Mérieux Equity Partners make money?
Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.
Who are Mérieux Equity Partners's main competitors?
Direct peers on record are Keensight Capital, ArchiMed, GHO Capital Partners, Andera Partners and Sofinnova Partners. Broad incumbents are EQT Life Sciences, Bain Capital Life Sciences, IK Partners and Novo Holdings. HealthTech investor (CapHorn) is listed as a regional player.
Does Mérieux Equity Partners have an API?
No public API is recorded for Mérieux Equity Partners.
What industry is Mérieux Equity Partners in?
Mérieux Equity Partners's product category is Healthcare Private Equity & Venture Capital. Its primary akta.pro industry code is FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms, with a secondary code of FSANAAAL, Venture Debt Providers. Its NAICS code is 525 and its SIC code is 6282.